Natasha Leskovsek

Cooley advised the underwriters of Heartflow, a leader in artificial intelligence technology for coronary artery disease, in connection with Heartflow’s $364.2 million upsized initial public offering.

Cooley advised MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products and delivery devices for patients with endocrine and orphan lung diseases, on an up to $500 million strategic financing agreement with funds managed by Blackstone.

Cooley advised Y-mAbs Therapeutics, a commercial-stage biopharmaceutical company focused on the development and commercialization of antibody-based therapeutics for the treatment of cancer, on its definitive merger agreement with SERB Pharmaceuticals. Under the agreement, SERB will acquire Y-mAbs, including its lead commercial oncology asset, DANYELZA, in an all-cash transaction representing an equity value of approximately $412 million.

Cooley advised Blue Owl (NYSE: OWL), a leading asset manager redefining alternatives, on an up to $500 million term loan facility for Madrigal Pharmaceuticals (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis.

Cooley advised Capstan Therapeutics, a clinical-stage biotechnology company with a mission to multiply therapeutic possibilities for patients through targeted in vivo RNA technologies, on its definitive agreement to be acquired by AbbVie.